menu
    • menu
    [{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fludrocortisone","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Fludrocortisone","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ MSD","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corporation \/ MSD"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Opevesostat","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":1.9199999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.9199999999999999,"dosageForm":"","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals for Opevesostat

    Menu

    Opevesostat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orion Corporation

                            Finland
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Merck & Co

                            Deal Size : $1,920.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Merck and Orion Mutual Option Exercise for Opevesostat in Prostate Cancer Treatment

                            Details : Through the license agreement, Merck will gain global rights to develop and commercialize MK-5684 (opevesostat), which is being evaluated for metastatic castration-resistant prostate cancer.

                            Brand Name : MK-5684

                            Molecule Type : Small molecule

                            Upfront Cash : $290.0 million

                            July 01, 2024

                            Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Merck & Co

                            Deal Size : $1,920.0 million

                            Deal Type : Licensing Agreement

                            Fermion Orion Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orion Corporation

                            Finland
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opevesostat,Glucocorticoid,Fludrocortisone Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : MSD Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orion and MSD Announce Global Collaboration for The Development and Commercialisation Of ODM-208, An Investiga...

                            Details : ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

                            Brand Name : ODM-208

                            Molecule Type : Small molecule

                            Upfront Cash : $290.0 million

                            July 13, 2022

                            Lead Product(s) : Opevesostat,Glucocorticoid,Fludrocortisone Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : MSD Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Fermion Orion Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Orion Corporation

                            Finland
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opevesostat,Glucocorticoid,Fludrocortisone Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU

                            Details : ODM-208 is a novel, oral, non-steroidal and selective inhibitor of CYP11A1 enzyme developed by Orion for the treatment of prostate cancer. ODM-208 suppresses the production of all steroid hormones and their precursors that may activate AR signalling path...

                            Brand Name : ODM-208

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 18, 2022

                            Lead Product(s) : Opevesostat,Glucocorticoid,Fludrocortisone Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Fermion Orion Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth